In a JAMA Network Open study, researchers found no evidence of neuroinflammation or blood-brain barrier dysfunction in cerebrospinal fluid markers of individuals with post-COVID-19 condition and neuropsychiatric symptoms compared to controls. The study, which assessed cytokines, chemokines, and neuroinflammation markers, suggests that persistent central nervous system immune activation may not be the primary driver of neurological long COVID symptoms.
In new draft guidance for manufacturing inspections, FDA draws inspiration from pandemic methods
The FDA published new manufacturing guidelines on Wednesday detailing “alternative tools” to assess drug manufacturing facilities in pending applications. The guidance outlines methods previously used
September 22, 2023